InDex Pharmaceuticals Holding AB (1NP1) AI Stock Analysis

5 Followers

InDex Pharmaceuticals Holding AB

(Frankfurt:1NP1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageExceptionally low leverage gives InDex greater financial flexibility than a highly indebted biotech. Limited debt reduces mandatory financing pressure and interest exposure, helping preserve strategic options while clinical, regulatory, and partnering activities continue.

Negative Factors

Persistent cash burnOngoing negative operating and free cash flow means InDex is consuming cash rather than funding development internally. Persistent burn increases the importance of future financing, partnerships, or asset monetization and can constrain the pace of clinical and regulatory execution.

InDex Pharmaceuticals Holding AB (1NP1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 106.61M
Dividend Yield: ―
Average Volume (3M): 8,403
Price to Earnings (P/E): -1.1
Beta (1Y): 0.10
Revenue Growth: -180.59%
EPS Growth: -265.58%
Country: Germany
Employees: 8
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

InDex Pharmaceuticals Holding AB Business Overview & Revenue Model

Company Description

Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producin...

InDex Pharmaceuticals Holding AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1NP1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	83Outperform	SEK 391.34M	2.04	63.09%	―	―	―
SE:HNSA	60Neutral	SEK 4.77B	-5.93	―	―	68.88%	10.63%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:VICO	44Neutral	SEK 3.02B	-5.70	-55.97%	―	-54.97%	-1.66%
SE:BINV	43Neutral	SEK 191.82M	-0.39	-128.54%	―	-83.67%	-50.29%
SE:SYNACT	43Neutral	SEK 743.15M	-7.07	-60.58%	―	―	14.35%

* Healthcare Sector Average

Performance Comparison

DE:1NP1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1NP1	InDex Pharmaceuticals Holding AB	1.00	-2.01	-66.86%
SE:HNSA	Hansa Biopharma	46.84	20.60	78.51%
SE:BINV	BioInvent International AB	2.92	-26.98	-90.25%
SE:SYNACT	SynAct Pharma AB	13.22	-7.88	-37.35%
SE:VICO	Vicore Pharma Holding AB	10.72	0.78	7.85%
SE:CANTA	Cantargia AB	1.39	-2.06	-59.77%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

InDex Pharmaceuticals Holding AB AI Stock Analysis